Axonics, Inc. (AXNX)

NASDAQ: AXNX · IEX Real-Time Price · USD
67.20
-0.14 (-0.21%)
Apr 17, 2024, 4:00 PM EDT - Market closed
-0.21%
Market Cap 3.43B
Revenue (ttm) 366.38M
Net Income (ttm) -6.09M
Shares Out 51.00M
EPS (ttm) -0.12
PE Ratio n/a
Forward PE 179.27
Dividend n/a
Ex-Dividend Date n/a
Volume 581,736
Open 67.33
Previous Close 67.34
Day's Range 67.15 - 67.46
52-Week Range 47.59 - 69.68
Beta 0.59
Analysts Hold
Price Target 71.25 (+6.03%)
Earnings Date Apr 29, 2024

About AXNX

Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to r... [Read more]

Industry Medical Devices
Sector Healthcare
CEO Raymond W. Cohen
Employees 797
Stock Exchange NASDAQ
Ticker Symbol AXNX
Full Company Profile

Financial Performance

In 2023, Axonics's revenue was $366.38 million, an increase of 33.86% compared to the previous year's $273.70 million. Losses were -$6.09 million, -89.80% less than in 2022.

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for AXNX stock is "Hold." The 12-month stock price forecast is $71.25, which is an increase of 6.03% from the latest price.

Price Target
$71.25
(6.03% upside)
Analyst Consensus: Hold
Stock Forecasts

News

FTC seeks more information on Boston Scientific's $3.7 bln Axonics deal

Boston Scientific said on Thursday the U.S. Federal Trade Commission (FTC) has requested additional information from the medical device maker related to its $3.7 billion deal to buy Axonics.

Other symbols: BSX
13 days ago - Reuters

Axonics Stockholders Approve Merger Agreement with Boston Scientific

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) announced that its stockholders have voted today to adopt Axonics' merger agreement with Boston Scientific Corporation (NYSE: BSX). Accord...

Other symbols: BSX
26 days ago - Business Wire

Axonics Provides Update on Inter Partes Review Proceedings

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has issued written decisions on two ...

27 days ago - Business Wire

Axonics Receives CE Mark Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunct...

5 weeks ago - Business Wire

Axonics Responds to ITC Action by Medtronic

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) today announced that it has received notice that Medtronic has filed a complaint with the U.S. International Trade Commission (ITC), along...

6 weeks ago - Business Wire

Axonics Reports Fourth Quarter and Fiscal Year 2023 Financial Results

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunct...

7 weeks ago - Business Wire

AXONICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Axonics, Inc. - AXNX

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Axonics, Inc. (N...

Other symbols: BSX
7 weeks ago - Business Wire

Boston Scientific Announces Results for Fourth Quarter and Full Year 2023

MARLBOROUGH, Mass. , Jan. 31, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.725 billion during the fourth quarter of 2023, growing 14.9 percent on a reported...

Other symbols: BSX
2 months ago - PRNewsWire

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Axonics, Inc.

NEW YORK , Jan. 8, 2024 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Axonics, Inc. (NASDAQ: AXNX) and its board of directors concerning the proposed acquisit...

Other symbols: BSX
3 months ago - PRNewsWire

Shareholder Alert: Ademi LLP investigates whether Axonics, Inc. has obtained a Fair Price in its transaction with Boston Scientific

MILWAUKEE , Jan. 8, 2024 /PRNewswire/ -- Ademi LLP is investigating Axonics (Nasdaq: AXNX) for possible breaches of fiduciary duty and other violations of law in its transaction with Boston Scientific...

3 months ago - PRNewsWire

AXNX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Axonics, Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Axonics, Inc. (NASDAQ: AXNX) to Boston Scientific Corporation for $71.00 in cash per shar...

3 months ago - Business Wire

Axonics Stock Soars. It's Being Acquired By Boston Scientific In $3.7 Billion Deal.

The move will expand Boston's product portfolio in its urology business.

Other symbols: BSX
3 months ago - Barrons

Boston Scientific To Acquire Axonics For About $3.7 Bln

Axonics had agreed to be bought for $71 a share. Boston Scientific said the deal gave Axonics an equity value of $3.7 billion and an enterprise value of $3.4 billion.

Other symbols: BSX
3 months ago - WSJ

Boston Scientific to buy Axonics for $3.7 billion

Boston Scientific said on Monday it had agreed to buy medtech company Axonics Inc for $3.7 billion.

Other symbols: BSX
3 months ago - Reuters

Axonics Reports Preliminary 4Q23 and Fiscal Year 2023 Revenue

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunct...

3 months ago - Business Wire

Boston Scientific Announces Agreement to Acquire Axonics, Inc.

Acquisition to expand urology portfolio with differentiated technologies to treat urinary and bowel dysfunction MARLBOROUGH, Mass. , Jan. 8, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: B...

Other symbols: BSX
3 months ago - PRNewsWire

Axonics Announces Definitive Agreement to be Acquired by Boston Scientific

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) today announced that it has entered into a definitive agreement to be acquired by Boston Scientific Corporation (NYSE: BSX) for $71 in cas...

Other symbols: BSX
3 months ago - Business Wire

Axonics to Present at the J.P. Morgan Healthcare Conference

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunct...

4 months ago - Business Wire

BiVACOR Appoints Veteran Medical Device Executive Raymond W. Cohen as Chairman of the Board of Directors

HUNTINGTON BEACH, Calif.--(BUSINESS WIRE)--BiVACOR, Inc., a clinical-stage medical technology company developing a total artificial heart (TAH), today announced that Raymond W. Cohen has been appointe...

4 months ago - Business Wire

Goldman Sachs money manager digs into three themes for long-term growth

Most exchange-traded funds are passively managed — they are designed to mirror the performance of stock indexes and typically have low management fees. They can work out very well for investors, which...

4 months ago - Market Watch

Axonics to Participate in November Investor Conferences

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunct...

6 months ago - Business Wire

Axonics Reports Third Quarter 2023 Financial Results

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunct...

6 months ago - Business Wire

Axonics to Report Third Quarter 2023 Financial Results on October 30

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunct...

7 months ago - Business Wire

Axonics to Participate in September Investor Conferences

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunct...

8 months ago - Business Wire

Axonics Announces CFO Retirement and Appoints Successor

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunct...

8 months ago - Business Wire